Journal
MUSCLE & NERVE
Volume 56, Issue 5, Pages 943-953Publisher
WILEY
DOI: 10.1002/mus.25658
Keywords
adeno-associated virus; canine; gait; gene therapy; muscle; neuromuscular disease; myotubular myopathy
Categories
Funding
- Association Francaise contre les Myopathies (France)
- Myotubular Trust (UK)
- Genopole d'Evry (France)
- INSERM (France)
- U.S. NIH [R21 AR064503, R01 HL115001, R01AR044345, HD075802, K08 AR059750]
- Audentes Therapeutics, Inc.
- Muscular Dystrophy Association [MDA383249]
- MDA/MVP
- Joshua Frase Foundation
- Where There's a Will There's a Cure
- Peter Khuri Myopathy Research Foundation
- Senator Paul D Wellstone Muscular Dystrophy Cooperative Research Center, Seattle [NIH U54AR065139]
Ask authors/readers for more resources
Introduction: X-linked myotubular myopathy (XLMTM), a devastating pediatric disease caused by the absence of the protein myotubularin, results from mutations in the MTM1 gene. While there is no cure for XLMTM, we previously reported effects of MTM1 gene therapy using adeno-associated virus (AAV) vector on muscle weakness and pathology in MTM1-mutant dogs. Here, we followed 2 AAV-infused dogs over 4 years. Methods: We evaluated gait, strength, respiration, neurological function, muscle pathology, AAV vector copy number (VCN), and transgene expression. Results: Four years following AAV-mediated gene therapy, gait, respiratory performance, neurological function and pathology in AAV-infused XLMTM dogs remained comparable to their healthy littermate controls despite a decline in VCN and muscle strength. Conclusions: AAV-mediated gene transfer of MTM1 in young XLMTM dogs results in long-term expression of myotubularin transgene with normal muscular performance and neurological function in the absence of muscle pathology. These findings support a clinical trial in patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available